Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUX4: Personalized Maintenance Therapy vs Standard Treatment in Pemphigus
NCT05898308Phase 4Recruiting
- Sponsor
- Rouen University Hospital
- Start
- Dec 2024
- Primary completion
- May 2032
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of rituximab in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by Rouen University Hospital. Started Dec 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT05898308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898308.